First and Only Parp Inhibitor, LynparzaŽ (Olaparib) Approved as a First-line Maintenance Therapy Treatment in BRCA-Mutated Advanced Ovarian Cancer

Wednesday, May 8, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

_______________________________

i AstraZeneca Canada Inc., LynparzaŽ (olaparib) tablets. Product Monograph. May 2019.

ii Ibid.

iii Ibid.

iv Ibid.

v Ibid.

vi Ibid.

vii Ovarian Cancer Canada. About Ovarian Cancer. Accessed April 10, 2019. Available at: http://www.ovariancanada.org/about-ovarian-cancer

viii Canadian Cancer Society. Ovarian Cancer Statistics. Accessed April 10, 2019. Available at: http://www.cancer.ca/en/cancer-information/cancer-type/ovarian/statistics/?region=on

ix Ovarian Cancer Canada. About Ovarian Cancer. Disease Basics. Accessed April 10, 2019. Available at: https://ovariancanada.org/About-Ovarian-Cancer/Disease-Basics/What-is-ovarian-cancer



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store